- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco - For people with early Alzheimer's (MCI), HMTM improvement in cognition over pre-treatment baseline now shown to be sustained over 18 months ABERDEEN, Scotland and SINGAPORE, Dec. 1, 2022 /PRNewswire/ TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alzheimer's disease (AD), being the only company running late-stage clinical trials for a potential therapy designed to target the Tau pathology of Alzheimer's. Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy. As a hallmark of the disease, it is recognised as a key target for disease modifying treatments. This approach by TauRx contrasts to many in t
Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability Shareholder commitment to TauRxrepresents a significant success story for UK-based life sciences research and development in areas of great unmet medical need TauRxwill present the Phase 3 findings at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco ABERDEEN, Scotland and SINGAPORE, Nov. 14, 2022 /PRNewswire/ TauRx Pharmaceuticals Ltd is a global leader in tau-based research in Alzheimer's disease (AD). Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy. It is a hallmark of the disease recognised as an important potential target for treating AD. HMTM is an oral tau aggregation inhibitor, targeting this underlying pathology. Glen
Les personnes infectées par le variant Delta ont deux fois plus de risque d’être hospitalisées pour COVID-19 que celles contaminées par le variant Alpha, conclut une étude britannique publiée samedi.
Selon une étude britannique publiée samedi, le risque d'être admis à l'hôpital en étant positif à la Covid-19 est multiplié par 2,26 avec le variant Delta par rapport au variant Alpha.
Les personnes infectées par le variant Delta ont deux fois plus de risque d’être hospitalisées pour Covid-19 que celles contaminées par le variant Alpha, conclut une étude britannique publiée samedi.